Page 6 - Bart De Strooper News Today

Experts hailed full data Wednesday showing a new drug can slow cognitive decline in Alzheimer's patients, but warned improvements were comparatively small and the treatment can have serious side effects.

Lecanemab has become one of the first experimental dementia drugs to appear to slow the progression of cognitive decline.

Experts hailed full data Wednesday showing a new drug can slow cognitive decline in Alzheimer's patients, but warned improvements were comparatively small and the treatment can have serious side effects.

The experimental drug lecanemab shows "potential" as an Alzheimers disease treatment, according to new Phase 3 trial results, but the findings raise some safety concerns because of its association with

Experts have hailed the lecanemab as beginning of the end for Alzheimers after the drug was found to slow cognitive decline by more than a quarter in clinical trials in America, Europe and Asia.

Lecanemab modestly slows disease’s inevitable worsening, but it remains unclear how much of a difference it will make.

An experimental treatment for Alzheimer's disease developed by Eisai and Biogen has slowed the decline of cognitive abilities in patients who participated in a clinical trial, according to...

Experts hailed full data Wednesday showing a new drug can slow cognitive decline in Alzheimer's patients, but warned improvements were comparatively small and the treatment can have serious side effects.

Muna Therapeutics has been awarded a $4.9 million grant from The Michael J. Fox Foundation for Parkinson’s Research.

LifeArc and the UK Dementia Research Institute (UK DRI) have today launched a new partnership to accelerate development of new diagnostic tests, treatments, and devices from scientific research discoveries to benefit people with dementia, which around 900,000 people in the UK are living with.